Why Attend?

Breakthrough Insights:
- Dive deep into the latest advancements in oligonucleotide development, regulatory compliance, and CMC considerations.
- Discover cutting-edge strategies for oligonucleotide discovery and precision targeting.

Cutting-Edge Delivery Methods:
- Explore optimized delivery methodologies for oligonucleotide-based therapies, propelling the frontier of drug development forward.

Benchmark and Learn:
- Compare your strategies with leading big pharma case studies to advance your manufacturing and analytical techniques for advanced oligonucleotide synthesis.
- Gain insights from industry cross-collaboration, working groups, regulatory bodies, and senior big pharma and biotech experts driving genetic medicine advancements.

AI and Drug Discovery:
- Learn how AI is revolutionizing drug discovery, enabling sequence design, and unlocking undruggable proteins, and discover how these innovations can enhance your pipelines.

Innovative Technologies:
- Engage with the latest drug delivery technologies to optimize target specificity for RNA therapeutics and vaccines.

Don't Miss Out!

This transformative event is your chance to shape the future of therapeutic advancement. Network with key industry leaders, share knowledge, and discover new opportunities in oligonucleotide therapeutics and delivery.

Event Details:
- Date: September 9-10, 2024
- Location: Hilton London Kensington

Join us at SAE's 4th Annual Oligonucleotide Therapeutics and Delivery Conference and be part of the next wave of innovation in genetic medicine. Register now and help shape the future of therapeutic advancements!

URL:
Brochure: https://go.evvnt.com/2445926-2?pid=2588

Price:
Oligonucleotide Therapeutics and Delivery (EARLY BIRD DISCOUNT UNTIL 28/06/24): GBP 2099.00

Speakers: DAVID TEW - Senior Scientific Director, Enzyme Engineering and Biocatalysts (E2B), GSK, NAGY HABIB - Professor of Surgery, Imperial College London, Co-Founder, MiNA, Apterna and Dawn Therapeutics, PETER SMITH - Director, New Modalities Chemistry, AstraZeneca, SAMIR OUNZAIN - Senior Chief Executive Officer and Scientific Co-Founder, HAYA Therapeutics, THIERRY DORVAL - Head of Data Sciences and Data Management, Servier Pharmaceuticals, THOMAS THUM - Founder, Chief Scientific Officer and Chief Medical Officer, Cardior Pharmaceuticals GmbH